Chronic Migraine
BMJ 348:g141b, Schwedt, T.J., 2014
Botulinum Toxin A for Prophylactic Treatment of Migraine and Tension Headaches in Adults
JAMA 307:1736-1745, Jackson,J.L.,et al, 2012
Intravenous Dihydroergotamine for Inpatient Management of Refractory Primary Headaches
Neurol 77:1827-1832, Nagy, A.J.,et al, 2011
Chronic Daily Headache
NEJM 354:158-165, Dodick,D.W., 2006
Acupuncture for Chronic Headache in Primary Care: Large, Pragmatic, Randomised Trial
BMJ 328:744-747, Vickers,A.J.,et al, 2004
The Emergency Management of Headaches
The Neurologist 9:93-98, Green,M.W., 2003
Analgesic Use: A Predictor of Chronic Pain and Medication Overuse Headache
Neurol 61:160-164,154, Zwart,J.-A.,et al, 2003
Features of Medication Overuse Headache Following Overuse of Different Acute Headache Drugs
Neurol 59:1011-1014,972, Limmroth,V.,et al, 2002
Headache
BMJ 325:881-886, Steiner,T.J. &Fontebasso,M., 2002
Prevalence of Headache in an Elderly Population: Attack Frequency, Disability, and Use of Medication
JNNP 70:377-381, Prencipe,M.,et al, 2001
Characterization of Chronic Daily Headaches in Children in a Multidisciplinary Headache Center
Neurol 56:1032-1037, Hershey,A.D.,et al, 2001
Botulinum Toxin A,AdjunctiveTherapy for Refractory Headaches Associated with Pericranial Muscle Tension
Headache 38:468-471, Wheeler,A.H., 1998
Neuroimaging in Presumed Primary Headache Disorders
Semin Neurol 17:373-382, Frishberg,B.M., 1997
Coexistence of Migraine and Idiopathic Intracranial Hypertension without Papilledema
Neurol 46:1226-1230, Mathew,N.T.,et al, 1996
Classification of Daily and Near-Daily Headaches:Field Trial of Revised IHS Criteria
Neurol 47:871-875, Silberstein,S.D.,et al, 1996
Headache
JNNP 57:134-143, Pearce,J.M.S., 1994
Symptomatic and Prophylactic Treatment of Migraine and Tension-Type Headache
Neurol 42:16-21, Schulman,E.A.&Silberstein,S.D., 1992
Chronic Daily Headache
Neurol 42:32-36, Sheftell,F.D., 1992
Idiopathic Intracranial Hypertension Without Papilledema
Arch Neurol 48:392-399, Marcelis,J.&Silberstein,S.D., 1991
Genetic Causes of Cerebral Small Vessel Diseases, A Parctical Guide for Neurologists
Neurol 100:766-783, Manini,A.,&Pantoni,L., 2023
Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023
Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021
Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021
Burning Pain in the Legs
NEJM 383:e18, Sacks, C.A., 2020
One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020
Migraine
NEJM 383:1866-1876, Ashina, M., 2020
Migraine, hearing loss, and blurred vision in a young woman
Neurol 95:e2945-e2950, Sasikumar, S.,et al, 2020
Factors Associated with Risk of Recurrent Transient Global Amnesia
JAMA Neurol 77:1551-1558, Morris, K.A.,et al, 2020
Cyclic Vomiting Syndrome in Children
AJGH 2:doi:10.33552/AJGH.2020, Al-Ansari, N., 2020
Encephalopathy in a Large Cohort of British Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy Patients
Stroke 50:283-290, Drazyk, A.M.,et al, 2019
A Woman in her 40s with Transient Neurological Symptoms, Migraine Headaches, and Hearing Loss
JAMA Neurol 76:504-505, Roshal, D.A.,et al, 2019
Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019
Antiepileptic Drug Treatment Patterns in Women of Childbearing Age with Epilepsy
JAMA Neurol 76:783-790, Kim, H.,et al, 2019
Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019
Vestibular Migraine
BMJ 366:L4213, Li, V.,et al, 2019
Treatment Effects and Comorbid Diseases in 58 Patients with Visual Snow
Neurol 93:e398-e403, vanDongen, R.M.,et al, 2019
Acute Treatment of Migraine in Children and Adolescents
Neurol 93:487-499, Oskoui, M.,et al, 2019
Pharmacologic Treatment for Pediatric Migraine Prevention
Neurol 93:500-509, Oskoui, M.,et al, 2019
Fremanezumab versus Placebo for Migraine Prevention in Patients with Documented Failure to Up to Four Migraine Preventive Medication Classes (FOCUS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3� Trial
Lancet 394:1030-1040, Ferrari, M.D.,et al, 2019
Acute Vestibular Migraine Treatment with Noninvasive Vagus Nerve Stimulation
Neurol 93:e1715-e1719, Beh, S.C. & Friedman, D.I., 2019
Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019
Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019
Abdominal Migraine
BMJ 360;k179, Angus-Leppan, H.,et al, 2018
Noninvasive Vagus Nerve Stimulation as Acute Therapy for Migraine
Neurol 91:e364-e373, Tassorelli,C., et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018
Lasmiditan is an Effective Acute Treatment for Migraine
Neurol 91:e2222-e2232, Kuca, B.,et al, 2018
Migraine and Risk of Perioperative Ischemic Stroke and Hospital Readmission: Hospital Based Registry Study
BMJ 356:e6635, Timm. F.P.,et al, 2017